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http:WHAT THIS PAPER ADDS
Aortic dissection is deﬁned as acute within 14 days after onset of symptoms. This deﬁnition is used in trials and
in clinical practice. In contrast to patients with acute complications, such as rupture, rapid enlargement and
malperfusion, patients with chronic dissection are treated for aneurysm formation. In this study, a signiﬁcant
proportion of patients presented with acute complications requiring TEVAR 15-85 days after onset of aortic
dissection. This indicates that there is a sub-acute, unstable phase in the transition between acute and chronic
dissection during which acute and life-threatening complications might occur, which questions the relevance of
the current deﬁnition.Objectives: This study aims to assess the relevance of the deﬁnition of acute dissection, to analyse whether there
is a sub-acute phase and to determine early outcome of thoracic endovascular aortic repair (TEVAR) in acute
complicated type B aortic dissection.
Design: Dual-centre consecutive case series.
Materials: Between 1999 and 2011, 102 patients underwent TEVAR for non-traumatic acute complicated type B
dissection in Zurich, Switzerland, and Uppsala, Sweden. In addition, 22 patients treated for an acute dissection-
related complication occurring >14 days after onset of symptoms were included. Median age was 68 years, 35%
were women.
Methods: Demographic, procedural and outcome data were collected prospectively. The patients were followed
up on 1 January 2012.
Results: In the 22 sub-acute patients (18%), there were no early deaths or neurological complications. The
predominant complication in these patients was rapid aortic enlargement, whereas rupture was more prevalent
in patients treated within 14 days. In total, there were nine (7%) early deaths, three (2%) post-intervention
paraplegias and six cases of stroke (5%).
Conclusions: TEVAR was performed with low early mortality and few neurological complications. A signiﬁcant
proportion of patients presented with acute complications >14 days after onset of symptoms, indicative of
a sub-acute phase in the transition between acute and chronic dissection, questioning the relevance of the
current deﬁnition.
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According to the current deﬁnition, the dissection is acute
14 days from onset of symptoms, and treatment within this
time period is regarded as acute.4 The deﬁnition of acute
dissection was based on autopsy studies of patients with
aortic dissection of any type, showing that 74% of the deaths
fromcomplications ofdissectionoccurredwithin 2weeks.This
deﬁnition is used in trials and in everyday clinical practice. In
contrast to patients with acute complications, such as end-
organ malperfusion, rupture or rapid aortic enlargement,
patients with chronic dissection are commonly treated for
progressive dilatation and aneurysm formation. We have
previously questioned the 2-weekdeﬁnition, whichwas based
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untreated, as clinical data indicated that it may take longer
than 2 weeks for a dissection to stabilise.5 In recent reports,
a subdivision of patients with acute complicated type B
dissection into acute (14 days), sub-acute (15e30 days) and
chronic (31e90 days) has been suggested, relating to the time
of onset of complications requiring intervention.1,6
The aims of this study were to determine early outcome of
TEVAR in patients with acute complicated type B dissection,
and to assess the relevance of the current deﬁnition of acute
dissection by merging data from two European tertiary
referral centres. Outcome of TEVAR in a subgroup of the
present patients has been published previously.5 That cohort
of patients has now been followed up for another 2 years,
and a large number of patients were added.MATERIALS AND METHODS
The TEVAR programme for acute aortic dissection was
initiated in 1999 at both participating tertiary referral
centres, the Zurich University Hospital, Switzerland, and the
Uppsala University Hospital, Sweden, respectively. During
a 12-year-period from the ﬁrst patient in 1999 until 31
December 2011, a total of 188 patients underwent TEVAR
for aortic dissection at the two centres. In all, 102 patients
were treated for non-traumatic acute complicated type B
dissection. In addition, 22 patients undergoing TEVAR for an
acute dissection-related complication occurring >14 days
after onset of symptoms were included in the study group,
which thus consisted of 124 patients. In the remaining 64
patients, who underwent TEVAR for aortic dissection but
who were not included in the present report, chronic type B
dissection with aneurysm formation was the indication for
TEVAR in 53 patients, acute type A dissection with distal
malperfusion in eight and chronic type A dissection in three.
Among the 124 included patients, 44 had a DeBakey type
IIIa dissection and 80 had type IIIb. Median age was 68
years, 35% were women. A total of 43 patients underwent
TEVAR within the ﬁrst 24 h. In the whole study group,
median time to TEVAR from the ﬁrst symptoms of aortic
dissection was 4 days, whereas among those who had
a complication within 2 weeks, median time was 2 days
(25e48 h after onset). In the 22 patients requiring treat-
ment after more than 14 days, median time to TEVAR was
23 days (range, 15e85 days) after the ﬁrst symptoms of
aortic dissection. All of these 22 patients underwent TEVAR
for an acute complication, that is, end-organ malperfusion,
rupture or rapid aortic enlargement, associated with
a deterioration of the clinical condition. The distribution of
time of TEVAR is depicted in Fig. 1(a) and (b).
On admission, the patients were assessed by a team of
vascular surgeons, radiologists, anaesthesiologists and angi-
ologists. Absence of signs of rupture or end-organ malperfu-
sion resulted in non-surgical management based on
alleviation of the pain and aggressive anti-hypertensive
management. The target upper limit of the systolic blood
pressure was 120 mmHg, aiming at 100-110 mmHg. The
purpose was to decrease aortic wall stress, but at the sametime maintaining adequate end-organ perfusion. First-line
treatment was beta-blocking agents. In the case of contra-
indication to beta-blockers or insufﬁcient effect, other anti-
hypertensive drugs were used. If no additional complica-
tions occurred, such patients could be discharged at the
discretion of the physician in charge after a hospital stay of
14 days, and after having undergone a pre-discharge
contrast-enhanced computed tomography (CT) of the
aorta. Patients who were still hospitalised and sustained
complications after >14 days after onset of symptoms and
patients who were re-admitted for acute complications
requiring TEVAR were categorised as sub-acute. There was
no pre-deﬁned upper time limit for categorisation as sub-
acute, as this was determined by the occurrence of acute
complications.The TEVAR and patientmanagement routines
at the two centres are virtually identical and follow the
principles of the Uppsala protocol which has been described
previously.5
Rupture and malperfusion in the setting of aortic
dissection, respectively, were deﬁned in accordance with
a recent report of the Society for Vascular Surgery (SVS).6
Demographic, peri- and postoperative data on the 124
patients undergoing TEVAR for non-traumatic acute or sub-
acute complicated type B aortic dissection were collected
prospectively. Early and long-term survival, as well as
complications, were registered until 31 December 2011. The
study was ethically approved by the Swedish Vascular
Registry (Swedvasc) steering committee and by the Insti-
tutional Review Board of the Zurich University Hospital.Statistical methods
Continuous variables were summarised with medians and
ranges and categorical variables with frequencies. Cate-
gorical data were analysed by the Fischer exact test; for age
comparisons, the ManneWhitney U test was used. Statis-
tical Package for the Social Sciences (SPSS) for Windows
20.0 was used for data processing and statistical analyses.
RESULTS
Baseline characteristics are given in Table 1, comparing the
acute and the sub-acute patient cohorts, respectively.
Patients with sub-acute onset of complications were younger
than those requiring TEVAR <14 days after the initial symp-
toms of aortic dissection. A high prevalence of hypertension
and proportion of smokers was observed in both groups.
In the entire cohort of 124 patients undergoing TEVAR for
acute non-traumatic type B aortic dissection, additional
stenting of one or more renal, visceral or lower-extremity
arteries was carried out in 31 patients (25%), and six
patients (5%) underwent endovascular fenestration, three of
whom also got one or more stents. One patient underwent
open membrane fenestration through a laparotomy. A total
of 89 patients (72%) were treated with TEVAR alone, and no
adjunctive procedures. The predominant indication for
TEVAR was rupture or contained rupture in 56 patients
(45%), severe malperfusion in 42 (34%), rapid enlargement
in 22 (18%) and intractable pain in four patients. Data on the
Figure 1. a. Distribution of patients undergoing TEVAR for acute (14 days) complicated type B aortic dissection in relation to day of
treatment. b. Distribution of patients undergoing TEVAR for subacute (15e90 days) complicated type B aortic dissection in relation to day
of treatment.
Table 1. Baseline characteristics of patients treated with TEVAR for
complicated type B dissection by time to onset of complication
requiring treatment.
Acute
(n ¼ 102)
Sub-acute
(n ¼ 22)
p value
Women 35 (34%) 8 (36%) 1.00
Median age (range) 69 (36e86) 58 (34e81) 0.012
Hypertension 70 (69%) 18 (82%) 0.21
Diabetes 4 (4%) 1 (5%) 1.00
Ischaemic heart disease 27 (26%) 4 (18%) 0.59
Peripheral vascular disease 18 (18%) 6 (27%) 0.37
Smoking 39 (38%) 13 (59%) 0.10
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Table 2. There were nine (7%) early deaths, three patients
(2%) had post-intervention paraplegia and six (5%) had
a stroke. In a total of 47 patients (38%) the left subclavian
artery was covered without prior revascularisation.
Among the 22 patients (18%) who had an acute
complication necessitating TEVAR more than 14 days after
onset of symptoms, rapid aortic enlargement was the
precipitating, predominant complication in 10 and end-
organ ischaemia in eight; there were two ruptures and
two cases of intractable pain. The eight patients with sub-
acute malperfusion underwent TEVAR after a median of
22 days (range, 15e38) after the onset of the acute
Table 2. Distal extension of aortic dissection and indication
for TEVAR and concomitant procedures (listed in italics) in
patients with type B dissection in relation to time to onset of
complications. Multiple indications may be present. Number of
patients in each category are given.
Acute
(n ¼ 102)
Sub-acute
(n ¼ 22)
p value
DeBakey type 0.22
IIIa 39 (38%) 5 (23%)
IIIb 63 (62%) 17 (77%)
Reno-visceral malperfusion 42 (41%) 8 (36%) 0.81
Coeliac trunk stent 1 1
SMA stent 4 1
Renal artery stent 15 1
Endovascular fenestration 5 0
Reno-visceral debranching 2 0
Leg ischaemia 18 (18%) 0 0.041
Iliac artery stent 10 0
Rupture/Haematoma/
Pleural effusion
59 (58%) 7 (32%) 0.034
Acute dilatation 13 (13%) 11 (50%) <0.001
Intractable pain 4 (4%) 2 (9%) 0.29
SMA ¼ Superior Mesenteric Artery.
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sub-acute patients whose main indication for TEVAR was
pain were treated after 20 and 23 days, respectively. Both
of them were still hospitalised after the primary onset of
dissection. In both cases, medical treatment of hyperten-
sion and the pain was undertaken primarily. In the patients
treated for sub-acute enlargement of the aorta, a dilatation
was noted in some cases in the ﬁrst 14 days, but there was
a continued rapid progression. In two of the patients onset
of new pain turned out to be indicative of rapid dilatation.
As seen in Table 2, multiple indications were present in
some patients. The distribution of complications occurring
in the sub-acute patients differed from those in patients
treated within 14 days (p < 0.0001). In this subset of
patients, median age was 58 years compared to 69 in those
operated on within 14 days (p ¼ 0.01). There were no early
deaths or neurological complications among the 22
patients with acute complications after more than 14 days.DISCUSSION
This study has demonstrated low early mortality and
acceptable rate of neurological complications in patients
undergoing TEVAR for acute or sub-acute complicated type
B aortic dissection. This further emphasises the beneﬁcial
and revolutionary role played by endografting of the
dissected aorta in this setting, and adds to previous
evidence.1,5e8
The study has also indicated that a subgroup of patients
sustaining type B aortic dissection needs particular atten-
tion even though the ﬁrst 14 days might be uneventful.
Until recently, there has been little debate regarding the
deﬁnition of acute dissection and the distinction between
acute and chronic. We questioned the relevance of the
14-day cut-off in a prior report,5 owing to the ﬁnding that
one in six patients treated for rupture, rapid aorticexpansion or aortic branch malperfusion in association with
type B dissection had onset of one or more of these life-
threatening complications >14 days after the initial symp-
toms of aortic dissection.
In the subset of sub-acute patients, the predominant
complication was rapid aortic enlargement, whereas rupture
was more prevalent in patients treated during the ﬁrst 2
weeks. Leg ischaemia, that is lower-extremity malperfusion
threatening the limb, requiring revascularisation for salvage,
did not occur in any of the sub-acute patients, whereas it was
seen in nearly one in ﬁve patients treated during the early
acute phase. The distal extension of the dissection with
regard to the DeBakey classiﬁcation did not differ between
the groups, however. Plausibly, this could indicate distal
stabilisation of the membrane in the sub-acute group. The
occurrence of acute limb ischaemia in acute type B dissection
has been shown to be associated with worse outcome, both
in the pre-TEVAR and current eras.9,10
The 14-day deﬁnition was applied in two recent rando-
mised trials of patients with type B aortic dissection: the
ADSORB11 study comparing best medical treatment (BMT)
with BMT and stent-grafting of the entry tear in patients
with uncomplicated acute type B dissection, randomising
patients within 14 days of onset of symptoms, and the
INSTEAD (Investigation Of Stent Grafts in Patients with type
B Aortic Dissection)12,13 study including patients considered
to have sustained an uncomplicated chronic dissection >14
days after onset, randomising the patients to BMT alone or
BMT and TEVAR with a median time of 6 weeks to ran-
domisation. The former study has been re-designed and is
still ongoing. At 1-year follow-up of the latter, seven (11%)
patients had crossed over from BMT alone to TEVAR, the
majority for aortic expansion to >60 mm, in one case for
late malperfusion. In the group of patients categorised as
having stable chronic dissection, there could thus have been
patients who, in fact, had unstable, sub-acute dissection.
In our series, there were no deaths or neurological
complications in the sub-acute cohort, which would indicate
that the current deﬁnition does have relevance. However,
there seems to be a transition between acute and chronic,
a period during which the ﬂap matures and stabilises. The
terms stable and unstable acute dissection, respectively,
have been suggested,14 and, as discussed by Tang and
Dake,15 increased ﬂap stability would make TEVAR safer, but
also decrease the success rate. Moreover, two recent
papers have sub-divided patients undergoing TEVAR >14
days after onset of an acute type B dissection into sub-acute
(15e30 days) and chronic (31e90 days).1,6 No group
comparisons were made with respect to complications, but
there was a tendency towards more rupture cases in the
acute group and more cases of expansion among the sub-
acute patients.1
Our study is limited by lack of data on patients admitted
to the two participating tertiary referral centres allocated to
non-surgical therapy. At our two centres, those patients are
mostly followed up by cardiologists or angiologists, whereas
patients having undergone TEVAR are under surveillance by
vascular surgeons. Our results support meticulous early
J. Steuer et al. 631monitoring of these patients and are suggestive of the need
to deﬁne a subset of patients that might beneﬁt from TEVAR
in uncomplicated dissection to prevent later complications.
Even though we did not experience any lethal complications
in the small cohort of patients with sub-acute dissection it is
likely that in a larger group of patients both death and major
morbidity would occur.
We conclude that a signiﬁcant proportion of patients
with acute type B dissection presented with complications
necessitating TEVAR more than 14 days after onset of
symptoms. Patients presenting with acute complications
after >14 days were younger and more often were treated
for rapid enlargement of the aorta, whereas rupture was
much more frequent in those undergoing TEVAR 14 days.
This indicates that there is a sub-acute, dynamic and/or
unstable phase in the transition between acute and chronic
dissection during which acute and life-threatening compli-
cations might occur and that the relevance of the old, and
commonly used, distinction between acute and chronic
dissection could be questioned. We suggest that future
trials and clinical surveillance and follow-up protocols
document patients treated during the sub-acute phase
separately and that this phase is deﬁned as 15e90 days
after onset of symptoms.CONFLICT OF INTEREST
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